Jazz Beats Cipla’s Bid to Knock 20 Epidiolex Patents From Suit

A federal judge rejected Cipla Ltd.'s arguments that 20 patents for Jazz Pharmaceuticals Plc’s epilepsy treatment Epidiolex are unenforceable, finding Jazz didn’t lie to the US Patent and Trademark Office when it filed applications as a “small entity.”

Judge Michael E. Farbiarz, in an opinion issued Thursday in the US District Court for the District of New Jersey, tossed a set of counterclaims from a case over several generic-drug makers’ proposed copies of Epidiolex. He called arguments by Cipla, its InvaGen Pharmaceuticals Inc. unit, and API Pharma Tech LLC—which supplies the active ingredient in their generic version of the drug—"not ...